Corbus Pharmaceuticals Holdings, Inc.
NASDAQRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for oncology and obesity by targeting well-understood biological pathways. The company's pipeline features three key investigational candidates: CRB-701, a next-generation antibody-drug conjugate targeting Nectin-4 expression on solid tumors to deliver a cytotoxic payload; CRB-601, an anti-integrin monoclonal antibody that blocks TGFβ activation in αvβ8-enriched solid tumors to enhance immune response; and CRB-913, a peripherally restricted CB1 receptor inverse agonist for obesity and related metabolic conditions. Founded in 2009 and headquartered in Norwood, Massachusetts, Corbus conducts clinical development primarily in the United States and Europe, with CRB-701 also sponsored by CSPC in China; it relies on third-party contract manufacturers and licensing partners for production. Recent developments include dosing the first patient in the CRB-601 Phase 1 trial in December 2024, expecting first patient in for CRB-913 in Q1 2025, expanding multiple cohorts for CRB-701, and raising $75 million in an underwritten public offering in November 2025 to fund pipeline advancement and general corporate purposes.
Company News
Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer
Is CRBP a Good Cannabis Investment After Positive Obesity Study Data?
Corbus CRB-913 Delivers 5% Weight Loss in Phase 1b Obesity Study
Corbus Pharmaceuticals Obesity Drug Avoids 'Depressive Effects'
Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity
Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity
Corbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity
Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer
Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer
Corbus Pharmaceuticals Teases Cancer, Obesity Data as Key Clinical Readouts Near
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Key Insights from HNSCC KOL Event Transcript
Corbus Pharmaceuticals Targets HPV-Linked Head and Neck Cancer With CRB-701 Study
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Clinical Data Update From Phase 1/2 Study of CRB-701 Presented at ASCO Transcript
Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers
Corbus Pharmaceuticals Teases Key ASCO Cancer Data, Late-Summer Obesity Readout
Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call
Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences
Corbus Pharmaceuticals Reports Q1 2026 Financial Results and Provides a Corporate Update